Timothy Rolph Biography and Net Worth

Co-Founder and Chief Scientific Officer of Akero Therapeutics

Tim Rolph is Co-Founder and Chief Scientific Officer of Akero. Prior to co-founding Akero, Tim led Pfizer’s Cardiovascular & Metabolic Disease Research Unit as Chief Scientific Officer. In his 22 years at Pfizer, Tim led anti-infective research at the company’s Sandwich (UK) laboratories, directing the team that discovered the prototype CCR5 antagonist, maraviroc, launched as a novel antiretroviral for HIV (Celzentry™), before becoming Head of Research in Sandwich and then at Pfizer’s Groton, Conn., laboratories. Under his leadership at Pfizer, Steglatro™ (ertugliflozin) was discovered and developed in partnership with Merck, and launched as a fixed-dose combination with sitagliptin (Steglujan™), a leading oral medication for diabetes. Prior to Pfizer, Tim worked in Glaxo’s veterinary R&D group, initially studying the modulation of growth for food production and then moving into anti-parasitic research for veterinary applications. Tim holds a B.Sc in Biochemistry from the University of London and a D.Phil from the Faculty of Clinical Medicine at the University of Oxford. His pre- and post-doctoral training was at the Nuffield Institute for Medical Research, where he studied the metabolic adaptations of skeletal and cardiac muscle during development.

What is Timothy Rolph's net worth?: The estimated net worth of Timothy Rolph is at least $9.10 million as of October 7th, 2025. Dr. Rolph owns 166,571 shares of Akero Therapeutics stock worth more than $9,099,774 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Rolph may own. Additionally, Dr. Rolph receives an annual salary of $722,320.00 as Co-Founder and Chief Scientific Officer at Akero Therapeutics. Learn More about Timothy Rolph's net worth.
How old is Timothy Rolph?: Dr. Rolph is currently 70 years old. There are 7 older executives and no younger executives at Akero Therapeutics. Learn More on Timothy Rolph's age.
What is Timothy Rolph's salary?: As the Co-Founder and Chief Scientific Officer of Akero Therapeutics, Inc., Dr. Rolph earns $722,320.00 per year. The highest earning executive at Akero Therapeutics is Dr. Andrew Cheng M.D., Ph.D., President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Timothy Rolph's salary.
How do I contact Timothy Rolph?: The corporate mailing address for Dr. Rolph and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at [email protected]. Learn More on Timothy Rolph's contact information.
Has Timothy Rolph been buying or selling shares of Akero Therapeutics?: During the last quarter, Timothy Rolph has sold $576,000.00 in Akero Therapeutics stock. Most recently, Timothy Rolph sold 12,500 shares of the business's stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $46.08, for a transaction totalling $576,000.00. Following the completion of the sale, the insider now directly owns 166,571 shares of the company's stock, valued at $7,675,591.68. Learn More on Timothy Rolph's trading history.
Who are Akero Therapeutics' active insiders?: Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), Scott Gangloff (CTO), Tomas Heyman (Director), Patrick Lamy (SVP of Commercial Strategy ), Timothy Rolph (Co-Founder and Chief Scientific Officer), Graham Walmsley (Director), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.
Are insiders buying or selling shares of Akero Therapeutics?: During the last twelve months, Akero Therapeutics insiders bought shares 3 times. They purchased a total of 341,309 shares worth more than $15,863,577.75. During the last twelve months, insiders at the sold shares 69 times. They sold a total of 737,859 shares worth more than $35,038,065.72. The most recent insider tranaction occured on October, 10th when CEO Andrew Cheng sold 30,000 shares worth more than $1,619,400.00. Insiders at Akero Therapeutics own 7.1% of the company. Learn More about insider trades at Akero Therapeutics.
Information on this page was last updated on 10/10/2025.

Timothy Rolph Insider Trading History at Akero Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/7/2025	Sell	12,500	$46.08	$576,000.00	166,571
9/11/2025	Sell	553	$43.02	$23,790.06	166,571
9/8/2025	Sell	12,500	$44.17	$552,125.00	167,124
8/5/2025	Sell	12,500	$49.30	$616,250.00	167,124
7/7/2025	Sell	12,500	$51.09	$638,625.00	167,124
6/18/2025	Sell	1,129	$54.84	$61,914.36	166,234
6/10/2025	Sell	2,358	$54.00	$127,332.00	167,363
6/6/2025	Sell	25,000	$55.04	$1,376,000.00	169,721
6/5/2025	Sell	12,500	$53.49	$668,625.00	169,721
5/6/2025	Sell	12,500	$43.43	$542,875.00	169,721
4/24/2025	Sell	6,250	$41.03	$256,437.50	169,721
4/7/2025	Sell	6,250	$35.88	$224,250.00	169,721
3/5/2025	Sell	12,500	$44.53	$556,625.00	170,237
2/5/2025	Sell	18,750	$56.51	$1,059,562.50	170,237
1/27/2025	Sell	31,250	$55.77	$1,742,812.50	170,237
12/10/2024	Sell	4,818	$30.91	$148,924.38	178,337
6/16/2023	Sell	78,200	$54.78	$4,283,796.00	151,220
6/13/2023	Sell	509	$55.16	$28,076.44	189,420
12/28/2022	Sell	1,700	$50.00	$85,000.00	203,032
11/15/2022	Sell	3,138	$45.04	$141,335.52	187,784
10/25/2022	Sell	10,653	$45.09	$480,343.77	195,684
10/6/2022	Sell	22,500	$39.29	$884,025.00	186,337
9/30/2022	Sell	45,000	$32.72	$1,472,400.00	198,837

Timothy Rolph Buying and Selling Activity at Akero Therapeutics

Akero Therapeutics Company Overview

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $54.63

$54.53

$54.69

50 Day Range

MA: $52.78

$46.00

$54.69

2 Week Range

Now: $54.63

$21.34

$58.40

Volume

2,283,430 shs

Average Volume

1,484,302 shs

Market Capitalization

$4.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Timothy Rolph Biography and Net Worth

What is Timothy Rolph's net worth?

How old is Timothy Rolph?

What is Timothy Rolph's salary?

How do I contact Timothy Rolph?

Has Timothy Rolph been buying or selling shares of Akero Therapeutics?

Who are Akero Therapeutics' active insiders?

Are insiders buying or selling shares of Akero Therapeutics?

Timothy Rolph Insider Trading History at Akero Therapeutics

Timothy Rolph Buying and Selling Activity at Akero Therapeutics

Akero Therapeutics Company Overview

Today's Range

50 Day Range

2 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta